@entity438 and @entity2849 with endovascular treatment in 12 XXXX .

@entity1 @entity438 @entity439 @entity2849 @entity7252
PURPOSE: To assess the endovascular treatment of @entity438 and @entity2849 . METHODS: Twelve @entity1 (mean age 59 years, range 47-75 years) with @entity438 (n = 10) or false @entity439 (n = 2) were treated. The lesion was asymptomatic in 11 @entity1 ; @entity7252 was observed in one @entity1 . The lesion was juxta-ostial in one case, located on the intermediate segment of the splenic artery in four, near the splenic hilus in six, and affected the whole length of the artery in one @entity1 . In 10 cases, the maximum lesion diameter was greater than 2 cm; in one case 30% growth of an @entity439 18 mm in diameter had occurred in 6 months; in the last case, two distal @entity439 were associated (17 and 18 mm in diameter). In one case, stent-grafting was attempted; one detachable balloon occlusion was performed; the 10 other @entity1 were treated with coils. RESULTS: Endovascular treatment was possible in 11 @entity1 (92%) (one failure: stenting attempt). In four cases among 11, the initial treatment was not successful (residual perfusion of @entity439 ); surgical treatment was carried out in one case, and a second embolization in two. Thus in nine cases (75%) endovascular treatment was successful: complete and persistent exclusion of the @entity439 but with spleen perfusion persisting at the end of follow-up on CT scans (mean 13 months). An early and transient elevation of pancreatic enzymes was observed in four cases. CONCLUSION: Ultrasound and CT have made the diagnosis of @entity438 or false @entity439 more frequent. Endovascular treatment, the morbidity of which is low, is effective and spares the spleen.
